Inhibitory Effect of PRMT5/ MTA Inhibitor on MTAP ‐Deficient Glioma May Be Influenced by Surrounding Normal Cells
Cancer Medicine · 2024
DOI: 10.1002/cam4.70526 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Yunjie Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation…. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Glioma, Purine-Nucleoside Phosphorylase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Youth Innovation Team Plan of Shandong Province, Talent Induction Program for Youth Innovation Teams in Colleges and Universities of Shandong Province and Initial Scientific Research Fund of Yantai University.
Abstract (Originalsprache)
Background
Methylthioadenosine phosphorylase (MTAP) and protein arginine methyltransferase 5 (PRMT5) are considered to be a synthetic lethal pair of targets, due to the fact that deletion of MTAP leads to massive production of methylthioadenosine (MTA) decreasing the activity of PRMT5. In vitro and in vivo experiments have demonstrated that MRTX1719, a small molecule that selectively binds PRMT5/MTA complex, significantly inhibits the proliferation of MTAP‐deficient tumors and has a weak toxic effect on normal cells. However, it has been reported that MTAP‐deleted tumors did not significantly accumulate MTA in vivo due to metabolism of MTA by MTAP‐expressing stroma, which might lead to a diminished anti‐cancer effect of MRTX1719.
Methods
We first analyzed whether there were MTAP‐expressing normal intracerebral cells around MTAP‐deficient glioma tissues by paraffin‐embedded tissue microarray of human glioma specimens. Then, in vivo and in vitro models of MTAP‐deficient gliomas coexisting with neurons or glial cells were constructed for evaluating the effectiveness of the anti‐tumor effects of MRTX1719 in this setting.
Results
MTAP‐deficient gliomas were surrounded by a large number of MTAP‐expressing normal cells, and the presence of these cells significantly reduced the inhibitory effect of MRTX1719 on MTAP‐deficient glioma cells in vitro and in vivo.
Conclusions
Due to the complexity of the tumor environment in vivo, the anti‐tumor effects of PRMT5/MTA‐specific inhibitors may be somewhat attenuated, and their ability to achieve suitable therapeutic effects in the clinic might require more in‐depth studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universi…
ORCID-Profile: Xiaohui Sun
Förderung
- Youth Innovation Team Plan of Shandong Province
- Talent Induction Program for Youth Innovation Teams in Colleges and Universities of Shandong Province and Initial Scientific Research Fund of Yantai University
Zitieren
APA
Wang, Y., Sun, X., Ma, R., Zhang, X., Ji, S., Liu, Z., Yang, G., Wang, H., Zhang, P., Zhang, J., & Tian, J. (2024). Inhibitory Effect of PRMT5/ MTA Inhibitor on MTAP ‐Deficient Glioma May Be Influenced by Surrounding Normal Cells. Cancer Medicine. https://doi.org/10.1002/cam4.70526
Vancouver
Wang Y, Sun X, Ma R, Zhang X, Ji S, Liu Z, et al. Inhibitory Effect of PRMT5/ MTA Inhibitor on MTAP ‐Deficient Glioma May Be Influenced by Surrounding Normal Cells. Cancer Medicine. 2024. doi:10.1002/cam4.70526
BibTeX
@article{Wang2024,
author = {Wang, Yunjie and Sun, Xiaohui and Ma, Runchen and Zhang, Xiaofan and Ji, Shengmin and Liu, Zhaofeng and Yang, Gangqiang and Wang, Hongbo and Zhang, Peng and Zhang, Jianzhao and Tian, Jingwei},
title = {Inhibitory Effect of PRMT5/ MTA Inhibitor on MTAP ‐Deficient Glioma May Be Influenced by Surrounding Normal Cells},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70526}
}
EUVIMED